Trinity Capital Pledges $50m Growth Investment in FDA-Cleared Tremor Therapy Maker
Trinity Capital has committed $50m of growth capital to Cala Health to expand its FDA-cleared transcutaneous afferent patterned stimulation wearables for essential tremor and Parkinson’s patients following FDA clearance of next-gen Cala kIQ Plus on April 15, 2026. The global neuromodulation device market is forecast to rise from $6bn in 2023 to nearly $11bn by 2033, underpinning potential returns on this investment.
1. Growth Capital Commitment
Trinity Capital has committed $50m of growth capital to Cala Health, providing funding to expand its neuromodulation therapy for tremor management. The investment is structured to optimize Trinity’s capital deployment and accelerate commercial expansion and product innovation for Cala Health.
2. Cala’s FDA-Cleared TAPS Devices
Cala Health’s wrist-worn transcutaneous afferent patterned stimulation system, Cala kIQ, received FDA clearance in 2023, while the next-generation Cala kIQ Plus with new therapy modes and adaptive calibration secured clearance on April 15, 2026. These devices measure individual tremor patterns and deliver personalized nerve stimulation to counteract hand tremors in essential tremor and Parkinson’s patients.
3. Market Outlook and Strategic Rationale
The global neuromodulation device market is projected to grow from $6bn in 2023 to nearly $11bn by 2033, offering a substantial addressable market for Cala’s TAPS therapy. Trinity’s investment aligns with its strategy to back high-growth medical technology ventures poised for market expansion.